ICU Pharmacotherapy MasterclassPain • RASS • Delirium • RSI • NMB • Liberation

Sedation, Analgesia & Neuromuscular Blockade

A bedside curriculum for choosing and titrating analgesics, sedatives and paralytics by goal, physiology and recovery plan—not by habit. The masterclass links directly to the full medication monographs for exact dosing, organ-failure guidance and claim-level evidence.

1. The bedside sequence

Every infusion should answer a clinical question: what symptom or behavior are you treating, and when will you reassess it?

Assess pain

Use self-report when possible; otherwise CPOT/BPS. Treat pain and procedural discomfort before escalating hypnotics.

Set a sedation target

Choose an explicit RASS/SAS goal. Light sedation is preferred when clinically feasible; deep sedation requires a reason.

Choose by phenotype

Match hemodynamics, respiratory drive, neurologic needs, organ failure and delirium risk to the agent.

Reassess / liberate

Use protocolized titration, spontaneous-awakening/breathing strategies when appropriate, and daily indication review.

Paralyze only with a plan

NMB requires guaranteed analgesia + amnesia, objective monitoring, eye/skin/DVT care and a stop/reassessment point.

2025 PADIS update: dexmedetomidine is conditionally suggested over propofol when light sedation and/or delirium reduction are the highest priorities. That is a phenotype-specific preference, not a declaration that dexmedetomidine is always the best ICU sedative.

2. Sedatives & analgesics — compare the tradeoffs

Scroll horizontally on mobile. Exact dosing remains on the linked monograph so the comparison stays focused on decision-making.

Agent	Best ICU role	Analgesia	Respiratory effect	Hemodynamics	Organ / accumulation issue	Bedside pearl
Propofol	Rapidly titratable hypnotic; useful when frequent awakening/neuro checks or deeper sedation is needed.	None	Marked dose-dependent respiratory depression	Vasodilation ± myocardial depression; hypotension is the key limitation	No fixed renal adjustment; prolonged/high-dose exposure raises triglyceride/PRIS concerns	Fast to titrate, but pain must be treated separately. Count lipid calories and watch for PRIS when exposure is prolonged/escalating.
Dexmedetomidine	Light, cooperative sedation; useful when wakefulness, communication or extubation are priorities.	Modest opioid-sparing effect; not sufficient for major pain alone	Minimal respiratory depression at usual sedative doses	Bradycardia/hypotension; loading can worsen instability	Hepatic clearance; titrate more cautiously in hepatic impairment	The 2025 PADIS focused update conditionally favors dexmedetomidine over propofol when light sedation and/or delirium reduction are highest priorities.
Midazolam	Selected deep sedation, seizures, alcohol/benzodiazepine withdrawal, or when other agents are unsuitable.	None	Strong respiratory depression, especially with opioids	Hypotension can occur, particularly in shock	Active metabolite can accumulate in renal dysfunction; hepatic dysfunction prolongs effect	Useful drug, but not the default for routine ventilator sedation because accumulation and delirium/prolonged awakening are important tradeoffs.
Ketamine	Analgesia, induction, bronchodilation, selected adjunctive analgosedation or opioid-sparing strategy.	Strong analgesic effect	Usually preserves spontaneous respiratory drive better than GABAergic sedatives, but apnea is still possible	Often sympathomimetic; hypotension may still occur in catecholamine-depleted shock	Hepatic metabolism; prolonged infusions require individualized monitoring	Do not interpret preserved blood pressure or breathing as guaranteed; shock physiology and co-administered sedatives matter.
Fentanyl	Rapid IV analgesia for ventilated or procedurally painful ICU patients.	Potent opioid analgesia	Dose-dependent respiratory depression	Usually modest direct vasodilation; bradycardia/hypotension can occur	No active renally cleared analgesic metabolite, but context-sensitive accumulation occurs with prolonged infusion	Fast and familiar, but high cumulative exposure can delay awakening; rapid large IV doses can cause chest-wall rigidity.
Hydromorphone	Intermittent IV opioid when longer analgesic effect is useful.	Potent opioid analgesia	Dose-dependent respiratory depression	Hypotension possible, especially with other sedatives	Hydromorphone-3-glucuronide accumulates in renal dysfunction and can cause neuroexcitation	Useful alternative to fentanyl, but dose/interval need particular caution in renal failure and opioid-naive patients.

3. Analgesia-first, not opioid-only

Measure pain

Use self-report whenever feasible. CPOT/BPS are for patients who cannot reliably self-report; vital signs alone are not a pain scale.

Use multimodal analgesia

Combine appropriate non-opioid and regional/local strategies with opioids when indicated. The goal is adequate analgesia with the smallest necessary opioid burden.

Reassess the consequence

Trend pain relief, ventilator synchrony, sedation, respiratory drive, ileus, delirium, withdrawal and time-to-awakening—not just the opioid dose.

Fentanyl

Synthetic Mu-Opioid Receptor Agonist

Potent synthetic mu-opioid agonist with rapid onset (1–2 min) and minimal clinically relevant histamine release compared with morphine; often useful when hemodynamic stability matters, but accumulation and delayed awakening can occur with prolonged/high-dose infusion.

Open full monograph →

Hydromorphone

Semi-Synthetic Mu-Opioid Receptor Agonist

Potent mu-opioid agonist for severe pain. It avoids morphine-6-glucuronide, but both hydromorphone exposure and hydromorphone-3-glucuronide can become clinically important in renal dysfunction; starting doses should be reduced in renal or hepatic impairment and titrated carefully.

Open full monograph →

Ketamine

Dissociative NMDA Receptor Antagonist

Dissociative NMDA antagonist providing analgesia, sedation, and bronchodilatory effects; often useful for RSI or selected ICU analgo-sedation scenarios, but not universally superior to other induction/sedation agents.

Open full monograph →

Naloxone

Opioid antagonist

Competitive opioid antagonist used to reverse clinically important opioid-induced respiratory/CNS depression while minimizing severe withdrawal.

Open full monograph →

4. Neuromuscular blockade / RSI

Paralysis solves movement, not pain, dyspnea or awareness. Sedation and analgesia are mandatory before and during ongoing blockade.

Agent	Onset	Duration	Elimination	Best role	Key caution
Rocuronium	Fast at RSI doses	Intermediate; longer with higher RSI dosing	Predominantly hepatobiliary with some renal contribution	RSI when succinylcholine is contraindicated; ongoing blockade when protocolized	Longer paralysis may complicate neurologic assessment; ensure full sedation/analgesia and plan reversal/recovery
Succinylcholine	Very rapid	Very short in most patients	Plasma pseudocholinesterase	RSI when no contraindication and very short paralysis is desirable	Avoid when dangerous hyperkalemia risk, malignant-hyperthermia susceptibility, significant denervation/neuromuscular disease, or other monograph-listed contraindications exist
Cisatracurium	Slower than RSI-dose rocuronium/succinylcholine	Intermediate	Organ-independent Hofmann degradation is clinically useful	Continuous ICU blockade when truly indicated, including selected severe ARDS or refractory ventilator dyssynchrony	Paralysis does not provide sedation or analgesia; minimize duration and reassess the indication frequently

Never forget during paralysis

Confirm ongoing analgesia and amnesia; physiologic signs are unreliable indicators of awareness.
Use peripheral nerve stimulation together with clinical assessment; TOF is not the sole target.
Protect eyes/skin, continue VTE prevention and pulmonary care, and avoid unnecessary duration.
Document why paralysis is required and what will trigger reduction or discontinuation.

ARDS evidence boundary

Current ATS guidance conditionally suggests NMBAs in early severe ARDS (low-certainty evidence). This should not be converted into routine continuous paralysis for every ARDS patient; use it when the expected ventilation benefit outweighs immobility/weakness/sedation harms.

5. Monitoring stack

Pain

Self-report when possible; CPOT/BPS if unable to report. Reassess after every intervention.

Sedation

Use RASS/SAS and record an explicit target. Avoid defaulting every patient to the same number.

Delirium

CAM-ICU or ICDSC plus clinical assessment; correct reversible causes and use multicomponent prevention.

Hemodynamics

Continuous BP/HR for titratable IV sedatives; anticipate vasodilation, bradycardia or sympathetic effects by agent.

Respiration

Ventilator synchrony, respiratory drive, CO₂ and airway protection are part of drug titration—not separate problems.

NMB

TOF/peripheral nerve stimulation + clinical effect + ventilator goal; never infer adequate sedation from paralysis.

6. Special ICU phenotypes

Hemodynamic shock

Avoid reflexively loading dexmedetomidine or escalating propofol in an unstable patient. Correct preload/afterload/pump problems and use the minimum sedative dose compatible with safety. Ketamine may support sympathetic tone but can still produce hypotension when catecholamine reserve is exhausted.

Neurocritical care

Favor agents that permit the required neurologic examination and ICP/CPP strategy. Propofol is highly titratable and useful for seizures/ICP but can reduce MAP; prolonged benzodiazepines can obscure the exam.

Severe renal failure

Expect active-metabolite accumulation with midazolam and hydromorphone; fentanyl and cisatracurium may be operationally useful but still require clinical titration.

Severe hepatic failure

Dexmedetomidine, midazolam and several opioids can have prolonged exposure. Titrate to effect rather than applying routine rates without reassessment.

Obstructive lung disease

Avoid unnecessary respiratory-drive suppression when spontaneous ventilation matters. Ketamine can be a useful bronchodilating adjunct, but ventilator mechanics and adequate expiratory time remain the definitive treatment.

Withdrawal / seizures

Benzodiazepines remain important for alcohol/benzodiazepine withdrawal and many seizure protocols; this is a different indication from routine ventilator sedation.

7. Core monographs — exact dosing & safety

Propofol

Intravenous Sedative-Hypnotic Agent

Dose + pearl ▼

Dose framework: Current U.S. label for adult ICU sedation: when indicated, start 5 mcg/kg/min, increase by 5–10 mcg/kg/min at intervals of at least 5 minutes to effect, and use the minimum effective maintenance rate. Most adults require 5–50 mcg/kg/min, although higher rates may sometimes be needed; administration should not exceed 4 mg/kg/hour (~67 mcg/kg/min) unless benefits outweigh risks.

Bedside pearl: Propofol is formulated in 10% lipid emulsion — calculate 1.1 kcal/mL into total daily nutritional intake! With prolonged or escalating propofol exposure—especially high doses or severe critical illness—monitor triglycerides and maintain a low threshold to check CK, lactate/acid-base status, potassium and ECG when PRIS is suspected.

Open complete monograph →

Dexmedetomidine

Selective Alpha-2 Adrenergic Agonist

Dose + pearl ▼

Dose framework: U.S. prescribing information: ICU sedation maintenance 0.2–0.7 mcg/kg/h; a 1 mcg/kg loading infusion over 10 minutes is labeled for initiation, although a loading dose may be unnecessary when converting from another sedative and is often avoided in hemodynamically fragile ICU patients. The U.S. ICU-sedation indication states continuous infusion should not exceed 24 hours; longer courses and higher maintenance rates used in many ICUs are off-label and should be identified as such.

Bedside pearl: A loading dose is part of U.S. labeling for initiation in some adults, but it is commonly omitted in unstable ICU patients because loading can worsen bradycardia, hypotension, or transient hypertension. Individualize to hemodynamics and local protocol.

Open complete monograph →

Midazolam

Short-Acting Benzodiazepine

Dose + pearl ▼

Dose framework: For ICU sedation, use a carefully titrated IV infusion to the minimum dose needed for the sedation goal; product-label dosing and institutional protocols should guide initiation and titration. For status epilepticus, use a dedicated evidence-based seizure protocol rather than treating a single bolus/infusion recipe as universal.

Bedside pearl: Continuous midazolam is a labeled ICU-sedation option. SCCM PADIS conditionally favors propofol or dexmedetomidine over benzodiazepines for mechanically ventilated adults; this is not a prohibition on midazolam. Renal dysfunction can prolong midazolam/metabolite elimination and recovery.

Open complete monograph →

Ketamine

Dissociative NMDA Receptor Antagonist

Dose + pearl ▼

Dose framework: RSI induction is commonly about 1–2 mg/kg IV but should be reduced/titrated in profound shock. Sub-dissociative analgesia: commonly 0.1–0.3 mg/kg IV. ICU infusion dosing is indication- and protocol-dependent; routine ketamine monotherapy for analgo-sedation is not preferred when better-studied agents are available.

Bedside pearl: Ketamine is a useful RSI option in shock or severe bronchospasm, but it is not universally hemodynamically neutral; catecholamine-depleted patients can still become hypotensive, so titrate dose and prepare hemodynamic support.

Open complete monograph →

Fentanyl

Synthetic Mu-Opioid Receptor Agonist

Dose + pearl ▼

Dose framework: ICU analgesic dosing is indication-, tolerance- and protocol-dependent. Use small IV boluses or a titrated infusion to the lowest effective analgesic dose with close respiratory/hemodynamic monitoring; do not treat a single fixed infusion range as universally appropriate.

Bedside pearl: Fentanyl causes little clinically relevant histamine release compared with morphine, which can be useful when hypotension is a concern. It can still cause bradycardia, respiratory depression, chest-wall rigidity with rapid/high dosing, and hemodynamic effects; opioid choice should remain individualized.

Open complete monograph →

Hydromorphone

Semi-Synthetic Mu-Opioid Receptor Agonist

Dose + pearl ▼

Dose framework: For opioid-naive adults, current U.S. labeling lists an IV starting dose of 0.2–1 mg every 2–3 hours as needed, administered slowly over at least 2–3 minutes. ICU dosing must still be individualized for prior opioid exposure, age, organ function and sedation/respiratory risk; continuous-infusion dosing is protocol- and tolerance-dependent.

Bedside pearl: Hydromorphone is substantially more potent than morphine, but no single conversion ratio should be treated as exact. When rotating opioids, use a validated institutional conversion approach, reduce for incomplete cross-tolerance when appropriate, and titrate to effect.

Open complete monograph →

Rocuronium

Non-Depolarizing Aminosteroid Neuromuscular Blocking Agent

Dose + pearl ▼

Dose framework: For tracheal intubation, rocuronium dosing is weight- and context-dependent; 0.6 mg/kg is the labeled routine intubating dose and higher doses (including 1.0–1.2 mg/kg) are commonly used for RSI to accelerate onset, with longer duration. For obesity and prolonged ICU infusion, use current anesthesia/ICU protocols rather than a universal ideal-body-weight rule.

Bedside pearl: Rocuronium is a useful RSI alternative when succinylcholine-related hyperkalemia is a concern. Sugammadex can reverse profound rocuronium blockade, but it is not a substitute for a failed-airway plan and is not recommended by current U.S. labeling in severe renal impairment.

Open complete monograph →

Succinylcholine

Depolarizing Neuromuscular Blocking Agent

Dose + pearl ▼

Dose framework: Product Label Adult IV Intubation: 0.6 mg/kg IV (range 0.3–1.1 mg/kg IV). Clinical RSI Airway Strategy: 1.0–1.5 mg/kg IV (actual body weight).

Bedside pearl: Do not use a rigid potassium number or a single immobility time cutoff. Screen for conditions that upregulate extrajunctional ACh receptors (burns after the acute phase, denervation, major neuromuscular disease, prolonged critical illness/immobility, severe muscle injury) because the potassium rise can become life-threatening.

Open complete monograph →

Cisatracurium

Non-Depolarizing Benzylisoquinolinium NMBA

Dose + pearl ▼

Dose framework: When continuous neuromuscular blockade is clinically indicated, use a current ICU/anesthesia protocol and titrate to the minimum effective blockade. Do not present a single ARDS loading/infusion regimen as a universal guideline dose.

Bedside pearl: Cisatracurium is attractive in organ failure because recovery is predominantly organ-independent, but no NMBA should be called universally safest; titrate to the indication and neuromuscular effect.

Open complete monograph →

8. Resident progression — R1 to R5

Open the answer only after committing to a plan.

Pain before sedation

A newly intubated patient is tachycardic, grimacing and fighting the ventilator. No analgesic has been given. RASS is +2.

Show reasoning →

Reasoning: Treat pain first and reassess before simply escalating hypnotic sedation. Use a validated pain tool (e.g., CPOT/BPS when self-report is not possible), then set an explicit sedation target.

Light sedation and extubation

A ventilated patient is improving, but propofol causes recurrent hypotension. The goal is interactive light sedation while moving toward extubation.

Show reasoning →

Reasoning: Dexmedetomidine is a strong option when light cooperative sedation and/or delirium reduction are priorities, provided bradycardia/hypotension risk is acceptable. Do not use it as a substitute for analgesia.

Renal failure and delayed awakening

A patient with severe AKI has received a prolonged midazolam infusion and remains deeply sedated after it is stopped.

Show reasoning →

Reasoning: Consider benzodiazepine and active-metabolite accumulation as a major contributor. Reassess all sedative/opioid exposure, metabolic causes and neurologic pathology rather than assuming structural brain injury.

ARDS dyssynchrony

Severe early ARDS remains profoundly dyssynchronous despite lung-protective settings, proning and adequate analgosedation. Plateau/driving pressures worsen during active effort.

Show reasoning →

Reasoning: A time-limited NMBA strategy can be reasonable in selected early severe ARDS when deep sedation alone cannot achieve safe ventilation. Ensure adequate analgesia/amnesia first, use the minimum effective blockade, and reassess the need daily. ATS guidance is conditional rather than a mandate for routine paralysis.

Shock + bronchospasm + neuro assessment

A mechanically ventilated patient has severe bronchospasm, vasopressor-dependent shock and a need for serial neurologic assessment. You must balance analgesia, hypnotic choice, hemodynamics and ventilator synchrony.

Show reasoning →

Reasoning: There is no single perfect agent. Build the plan from the dominant problem: analgesia first; consider ketamine as an adjunct for pain/bronchodilation if appropriate, use the lowest titratable hypnotic burden compatible with safety, avoid assuming ketamine cannot cause hypotension in catecholamine depletion, and reserve paralysis for a defined indication with guaranteed analgesia/amnesia and a reassessment endpoint.

Evidence anchors

SCCM PADIS Focused Update 2025 ↗SCCM PADIS 2018 ↗ATS ARDS Guideline Update ↗